Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 7485-7490

  Al Kafaji, Ghada ^a   Al Mahroos, Ghazi ^b   Alsayed, Nasreen A ^c   Hasan, Zuheir A ^a   Nawaz, Sadia ^a   Bakhiet, Moiz ^a  

^a ARABIAN GULF UNIVERSITY   (Bahrain)

^b SALMANIYA MEDICAL COMPLEX   (Bahrain)

^c Gulf Diabetes Specialist Centre   (Bahrain)

Author keywords

Biomarker; MicroRNA; Peripheral blood microRNA 15a; Pre diabetes; Type 2 diabetes

Indexed keywords

BIOLOGICAL MARKER; GLUCOSE; MICRORNA 15A; MICRORNA; MIRN15 MICRORNA, HUMAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BLOOD; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION; GENETICS; MIDDLE AGED; PREDIABETIC STATE;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE EXPRESSION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; PREDIABETIC STATE; ROC CURVE;

EID: 84943635119     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4416     Document Type: Article

References (35)

1. Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047-1053, 2004.
2. Alhyas L, McKay A and Majeed A: Prevalence of type 2 diabetes in the states of the Co-operation council for the Arab states of the Gulf: A systematic review. PLoS One 7: e40948, 2012.
3. Abdul-Ghani MA and DeFronzo RA: Pathophysiology of prediabetes. Curr Diab Rep 9: 193-199, 2009.
4. Cavaghan MK, Ehrmann DA and Polonsky KS: Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 106: 329-333, 2000.
5. Harris MI, Klein R, Welborn TA and Knuiman MW: Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 15: 815-825, 1992.
6. Thompson TJ, Engelgau MM, Hegazy M, Ali MA, Sous ES, Badran A and Herman WH: The Onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med 13: 337-340, 1996.
7. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, et al: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350, 2001.
8. Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell 136: 215-233, 2009.
9. Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD and German MS: MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes 56: 2938-2945, 2007.
10. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewasky N, Rorsman P and Soffel M: A pancreatic islet-specific microRNA regulates insulin secretion. Nature 432: 226-230, 2004.
11. He A, Zhu L, Gupta N, Chang Y and Fang F: Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 21: 2785-2794, 2007.
12. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F and Regazzi R: MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem 281: 26932-26942, 2006.
13. Tang X, Tang G and Ozcan S: Role of microRNAs in diabetes. Biochimic Biophysic Acta 1779: 697-701, 2008.
14. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
15. Chen X, Liang H, Zhang J, Zen K and Zhang CY: Secreted microRNAs: A new form of intercellular communication. Trends Cell Biol 22: 125-132, 2012.
16. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y and Ochiya T: Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 285: 17442-17452, 2010.
17. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
18. Yang X, Zeng Z, Hou Y, Yuan T, Gao C, Jia W, Yi X and Liu M: MicroRNA-92a as a potential biomarker in diagnosis of colorectal cancer: A systematic review and meta-analysis. PLoS One 9: e88745, 2014.
19. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW and Jing Q: Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31: 659-666, 2010.
20. Fichtlscherer S, de Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, et al: Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 677-684, 2010.
21. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, Prokopi M, Mayr A, Weger S, Oberhollenzer F, Bonora E, et al: Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107: 810-817, 2010.
22. Roth P, Wischhusen J, Happold C, Chandran PA, Hofer S, Eisele G, Weller M and Keller A: A specific miRNA signature in the peripheral blood of glioblastoma patients. J Neurochem 118: 449-457, 2011.
23. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, et al: Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One 7: e29770, 2012.
24. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, Just S, Borries A, Rudloff J, Leidinger P, et al: MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. Basic Res Cardiol 106: 13-23, 2011.
25. Keller A, Leidinger P, Bauer A, Elsharawy A, Haas J, Backes C, Wendschlag A, Giese N, Tjaden C, Ott K, et al: Toward the blood-borne miRNome of human diseases. Nat Methods 8: 841-843, 2011.
26. Alberti KG and Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539-553, 1998.
27. Wong L, Lee K, Russell I and Chen C: Endogenous controls for realtime quantitation of miRNA using TaqMan® MicroRNA assays. Macmillan Publishers Ltd., New York, 2007.
28. Roggli E, Britan A, Gattesco S, Lin-Marq N, Abderrahmani A, Meda P and Regazzi R: Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic beta-cells. Diabetes 59: 978-986, 2010.
29. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, Rorsman P, Zavolan M and Stoffel M: miR-375 maintains normal pancreatic alpha-and beta-cell mass. Proc Natl Acad Sci USA 106: 5813-5818, 2009.
30. Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF and Jeyaseelan K: MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One 6: e22839, 2011.
31. Bandi N, Zbinden S, Gugger M, Arnold M, Kocher V, Hasan L, Kappeler A, Brunnet T and Vassella E: miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res 69: 5553-5559, 2009.
32. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, et al: miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005.
33. Sun LL, Jiang BG, Li WT, Zou JJ, Shi YQ and Liu ZM: MicroRNA-15a positively regulates insulin synthesis by inhibiting uncoupling protein-2 expression. Diabetes Res Clin Pract 91: 94-100, 2011.
34. Meigs JB, Muller DC, Nathan DM, Blake DR and Andres R; Baltimore Longitudinal Study of Aging: The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes 52: 1475-1484, 2003.
35. Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G, Cobelli C and Rizza R: Pathogenesis of pre-diabetes: Mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 55: 3536-3549, 2006.